| Schedule Of Segment Reporting Information |
| |
|
Consumer
Products Segment |
|
|
Specialty
Pharmaceutical Segment |
|
|
Consolidated
Totals |
|
| Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| June 30, 2017: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
4,081,832 |
|
|
$ |
– |
|
|
$ |
4,081,832 |
|
| Gross profit |
|
|
2,844,458 |
|
|
|
– |
|
|
|
2,844,458 |
|
| Gain on change in derivative liability |
|
|
27,288 |
|
|
|
– |
|
|
|
27,288 |
|
| Selling, general and administrative |
|
|
(3,447,786 |
) |
|
|
(77,987 |
) |
|
|
(3,525,773 |
) |
| Research and development |
|
|
(55,956 |
) |
|
|
(149,691 |
) |
|
|
(205,647 |
) |
| Operating loss |
|
$ |
(631,996 |
) |
|
$ |
(227,678 |
) |
|
$ |
(859,674 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| June 30, 2016: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
2,487,756 |
|
|
$ |
– |
|
|
$ |
2,487,756 |
|
| Gross profit |
|
|
1,664,327 |
|
|
|
– |
|
|
|
1,664,327 |
|
| Selling, general and administrative |
|
|
(3,262,917 |
) |
|
|
(122,809 |
) |
|
|
(3,385,726 |
) |
| Research and development |
|
|
(224,266 |
) |
|
|
(117,281 |
) |
|
|
(341,547 |
) |
| Operating loss |
|
$ |
(1,822,856 |
) |
|
$ |
(240,090 |
) |
|
$ |
(2,062,946 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Six Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| June 30, 2017: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
7,846,023 |
|
|
$ |
– |
|
|
$ |
7,846,023 |
|
| Gross profit |
|
|
5,277,462 |
|
|
|
– |
|
|
|
5,277,462 |
|
| Gain on change in derivative liability |
|
|
237,888 |
|
|
|
– |
|
|
|
237,888 |
|
| Royalty buy-out |
|
|
– |
|
|
|
(2,432,000 |
) |
|
|
(2,432,000 |
) |
| Selling, general and administrative |
|
|
(7,052,962 |
) |
|
|
(149,520 |
) |
|
|
(7,202,482 |
) |
| Research and development |
|
|
(104,989 |
) |
|
|
(289,374 |
) |
|
|
(394,363 |
) |
| Operating loss |
|
$ |
(1,642,601 |
) |
|
$ |
(2,870,894 |
) |
|
$ |
(4,513,495 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Six Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| June 30, 2016: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
4,910,434 |
|
|
$ |
– |
|
|
$ |
4,910,434 |
|
| Gross profit |
|
|
3,289,962 |
|
|
|
– |
|
|
|
3,289,962 |
|
| Selling, general and administrative |
|
|
(5,952,161 |
) |
|
|
(122,809 |
) |
|
|
(6,074,970 |
) |
| Research and development |
|
|
(366,079 |
) |
|
|
(117,281 |
) |
|
|
(483,360 |
) |
| Operating loss |
|
$ |
(3,028,278 |
) |
|
$ |
(240,090 |
) |
|
$ |
(3,268,368 |
) |
|